Spectrum of Neuroradiologic Findings Associated with Monogenic Interferonopathies

References

1. 1.↵
   1. Crow YJ,
   2. Manel N

   . Aicardi–Goutières syndrome and the type I interferonopathies. Nat Rev Immunol 2015;15:429–40 doi:10.1038/nri3850 pmid:26052098

   CrossRefPubMed
2. 2.↵
   1. Lee-Kirsch MA

   . The type I interferonopathies. Annu Rev Med 2017;68:297–315 doi:10.1146/annurev-med-050715-104506 pmid:27813875

   CrossRefPubMed
3. 3.↵
   1. Eleftheriou D,
   2. Brogan PA

   . Genetic interferonopathies: an overview. Best Pract Res Clin Rheumatol 2017;31:441–59 doi:10.1016/j.berh.2017.12.002 pmid:29773266

   CrossRefPubMed
4. 4.↵
   1. Volpi S,
   2. Picco P,
   3. Caorsi R, et al

   . Type I interferonopathies in pediatric rheumatology. Pediatr Rheumatol Online 2016;14:35 doi:10.1186/s12969-016-0094-4 pmid:27260006

   CrossRefPubMed
5. 5.↵
   1. McGlasson S,
   2. Jury A,
   3. Jackson A, et al

   . Type I interferon dysregulation and neurological disease. Nat Rev Neurol 2015;11:515–23 doi:10.1038/nrneurol.2015.143 pmid:26303851

   CrossRefPubMed
6. 6.↵
   1. Aicardi J,
   2. Goutières F

   . A progressive familial encephalopathy in infancy with calcifications of the basal ganglia and chronic cerebrospinal fluid lymphocytosis. Ann Neurol 1984;15:49–54 doi:10.1002/ana.410150109 pmid:6712192

   CrossRefPubMedWeb of Science
7. 7.↵
   1. Crow YJ,
   2. Chase DS,
   3. Schmidt JL, et al

   . Characterization of human disease phenotypes associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, ADAR, and IFIH1. Am J Med Genet 2015;167:296–312 doi:10.1002/ajmg.a.36887 pmid:25604658

   CrossRefPubMed
8. 8.↵
   1. Clarke SL,
   2. Robertson L,
   3. Rice GI, et al

   . Type 1 interferonopathy presenting as juvenile idiopathic arthritis with interstitial lung disease: report of a new phenotype. Pediatr Rheumatol Online 2020;18:37 doi:10.1186/s12969-020-00425-w pmid:32398023

   CrossRefPubMed
9. 9.↵
   1. Clarke SL,
   2. Pellowe EJ,
   3. de Jesus AA, et al

   . Interstitial lung disease caused by STING-associated vasculopathy with onset in infancy. Am J Respir Crit Care Med 2016;194:639–42 doi:10.1164/rccm.201510-2102LE pmid:27585386

   CrossRefPubMed
10. 10.↵
    1. Li J,
    2. An S,
    3. Du Z

    . Familial interstitial lung disease caused by mutation of the STING1 gene. Front Pediatr 2020;8:543 doi:10.3389/fped.2020.00543 pmid:33014937

    CrossRefPubMed
11. 11.↵
    1. Mulhern CM,
    2. Hong Y,
    3. Omoyinmi E, et al

    . Janus kinase 1/2 inhibition for the treatment of autoinflammation associated with heterozygous TNFAIP3 mutation. J Allergy Clin Immunol 2019;144:863–66.e5 doi:10.1016/j.jaci.2019.05.026 pmid:31175876

    CrossRefPubMed
12. 12.↵
    1. Schwartz DM,
    2. Blackstone SA,
    3. Sampaio-Moura N, et al

    . Type I interferon signature predicts response to Janus kinase inhibition in haploinsufficiency of A20. Ann Rheum Dis 2020;79:429–31 doi:10.1136/annrheumdis-2019-215918 pmid:31767699

    FREE Full Text
13. 13.↵
    1. Meuwissen ME,
    2. Schot R,
    3. Buta S, et al

    . Human USP18 deficiency underlies type 1 interferonopathy leading to severe pseudo-TORCH syndrome. J Exp Med 2016;213:1163–74 doi:10.1084/jem.20151529 pmid:27325888

    Abstract/FREE Full Text
14. 14.↵
    1. Uzgil B,
    2. Scherr EH

    . Neuroimaging in Aicardi-Goutieres syndrome. Neurology 2016;86:15–16 doi:10.1212/WNL.0000000000002227 pmid:22156987

    CrossRefPubMed
15. 15.↵
    1. Uggetti C,
    2. Piana RL,
    3. Orcesi S, et al

    . Aicardi-Goutières syndrome: neuroradiologic findings and follow-up. AJNR Am J Neuroradiol 2009;30:1971–76 doi:10.3174/ajnr.A1694 pmid:19628626

    Abstract/FREE Full Text
16. 16.↵
    1. Uggenti C,
    2. Lepelley A,
    3. Depp M, et al

    . cGAS-mediated induction of type I interferon due to inborn errors of histone pre-mRNA processing. Nat Genet 2020;52:1364–72 doi:10.1038/s41588-020-00737-3 pmid:33230297

    CrossRefPubMed
17. 17.↵
    1. Livingston J,
    2. Crow Y

    . Neurologic phenotypes associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, ADAR1, and IFIH1: Aicard-Goutières syndrome and beyond. Neuropediatrics 2016;47:355–60 doi:10.1055/s-0036-1592307 pmid:27643693

    CrossRefPubMed
18. 18.↵
    1. La Piana R,
    2. Uggetti C,
    3. Roncarolo F, et al

    . Neuroradiologic patterns and novel imaging findings in Aicardi-Goutières syndrome. Neurology 2016;86:28–35 doi:10.1212/WNL.0000000000002228 pmid:26581299

    Abstract/FREE Full Text
19. 19.↵
    1. Ramesh V,
    2. Bernardi B,
    3. Stafa A, et al

    . Intracerebral large artery disease in Aicardi-Goutières syndrome implicates SAMHD1 in vascular homeostasis: SAMHD1 and intracerebral large artery disease. Dev Med Child Neurol 2010;52:725–32 doi:10.1111/j.1469-8749.2010.03727.x pmid:20653736

    CrossRefPubMedWeb of Science
20. 20.↵
    1. Livingston JH,
    2. Lin JP,
    3. Dale RC, et al

    . A type I interferon signature identifies bilateral striatal necrosis due to mutations in ADAR1. J Med Genet 2014;51:76–82 doi:10.1136/jmedgenet-2013-102038 pmid:24262145

    Abstract/FREE Full Text
21. 21.↵
    1. Ma L,
    2. Zhou Y,
    3. Zhang Y, et al

    . Role of A20 in interferon-α-mediated functional restoration of myeloid dendritic cells in patients with chronic hepatitis C. Immunology 2014;143:670–78 doi:10.1111/imm.12350 pmid:24965710

    CrossRefPubMed
22. 22.↵
    1. Gilani A,
    2. Adang LA,
    3. Vanderver A, et al

    . Neuropathological findings in a case of IFIH1-related Aicardi-Goutières syndrome. Pediatr Dev Pathol 2019;22:566–70 doi:10.1177/1093526619837797 pmid:30952201

    CrossRefPubMed
23. 23.↵
    1. Barth PG

    . The neuropathology of Aicardi-Goutières syndrome. Eur J Paediatr Neurol 2002;6(Suppl A):A27–31; discussion A37–39, A77–86 doi:10.1053/ejpn.2002.0570 pmid:12365358

    CrossRefPubMed
24. 24.↵
    1. Klok MD,
    2. Bakels HS,
    3. Postma NL, et al

    . Interferon-α and the calcifying microangiopathy in Aicardi-Goutières syndrome. Ann Clin Transl Neurol 2015;2:774–79 doi:10.1002/acn3.213 pmid:26273690

    CrossRefPubMed
25. 25.↵
    1. Piccoli C,
    2. Bronner N,
    3. Gavazzi F, et al

    . Late-onset Aicardi Goutières syndrome: a characterization of presenting clinical features. Pediatr Neurol 2021;115:1–6 doi:10.1016/j.pediatrneurol.2020.10.012 pmid:33307271

    CrossRefPubMed
26. 26.↵
    1. Vanderver A,
    2. Prust M,
    3. Kadom N, et al

    . Early-onset Aicardi-Goutières Syndrome: magnetic resonance imaging (MRI) pattern recognition. J Child Neurol 2015;30:1343–48 doi:10.1177/0883073814562252 pmid:25535058

    CrossRefPubMed
27. 27.↵
    1. Abdel-Salam GM,
    2. Abdel-Hamid MS,
    3. Mohammad SA, et al

    . Aicardi-Goutières syndrome: unusual neuro-radiological manifestations. Metab Brain Dis 2017;32:679–83 doi:10.1007/s11011-017-9993-4 pmid:28332073

    CrossRefPubMed
28. 28.↵
    1. Wu CC,
    2. Peng SS,
    3. Lee WT

    . Intracerebral large artery disease in Aicardi-Goutières syndrome with TREX1 mutation: a case report. Neurol Sci 2020;41:3353–56 doi:10.1007/s10072-020-04516-0 pmid:32524323

    CrossRefPubMed
29. 29.↵
    1. La Piana R,
    2. Uggetti C,
    3. Olivieri I, et al

    . Bilateral striatal necrosis in two subjects with Aicardi-Goutières syndrome due to mutations in ADAR1 (AGS6). Am J Med Genet A 2014;164A:815–19 doi:10.1002/ajmg.a.36360 pmid:24376015

    CrossRefPubMed
30. 30.↵
    1. Vedrenne V,
    2. Gowher A,
    3. De Lonlay P, et al

    . Mutation in PNPT1, which encodes a polyribonucleotide nucleotidyltransferase, impairs RNA import into mitochondria and causes respiratory-chain deficiency. Am J Hum Genet 2012;91:912–18 doi:10.1016/j.ajhg.2012.09.001 pmid:23084291

    CrossRefPubMed
31. 31.↵
    1. Cirillo G,
    2. Cirillo M,
    3. Panetsos F, et al

    . Selective vulnerability of basal ganglia: insights into the mechanisms of bilateral striatal necrosis. J Neuropathol Exp Neurol 2019;78:123–19 doi:10.1093/jnen/nly123 pmid:30605553

    CrossRefPubMed
32. 32.↵
    1. Weerasekare J,
    2. Kassa R,
    3. Keegan BM

    . Retinal vasculopathy with cerebral leukoencephalopathy due to TREX-1 mutation: an important mimicker of CNS inflammatory disease. Mult Scler Relat Disord 2021;47:102639 doi:10.1016/j.msard.2020.102639 pmid:33254089

    CrossRefPubMed
33. 33.↵
    1. Alsohime F,
    2. Martin-Fernandez M,
    3. Temsah MH, et al

    . Janus kinase inhibitor therapy in a child with inherited USP18 deficiency. N Engl J Med 2020;382:256–65 doi:10.1056/NEJMoa1905633 pmid:31940699

    CrossRefPubMed
34. 34.↵
    1. Duncan CJ,
    2. Thompson B,
    3. Chen R, et al

    . Severe type I interferonopathy and unrestrained interferon signaling due to a homozygous germline mutation in STAT2. Sci Immunol 2019;4:eaav7501 doi:10.1126/sciimmunol.aav7501 pmid:31836668

    Abstract/FREE Full Text
35. 35.↵
    1. Livingston JH,
    2. Stivaros S,
    3. Warren D, et al

    . Intracranial calcification in childhood: a review of aetiologies and recognizable phenotypes. Dev Med Child Neurol 2014;56:612–26 doi:10.1111/dmcn.12359 pmid:24372060

    CrossRefPubMed
36. 36.↵
    1. Rönnblom L,
    2. Leonard D

    . Interferon pathway in SLE: one key to unlocking the mystery of the disease. Lupus Sci Med 2019;6:e000270 doi:10.1136/lupus-2018-000270 pmid:31497305

    Abstract/FREE Full Text
37. 37.↵
    1. Kim H,
    2. Gunter-Rahman F,
    3. McGrath JA, et al

    . Expression of interferon-regulated genes in juvenile dermatomyositis versus Mendelian autoinflammatory interferonopathies. Arthritis Res Ther 2020;22:69 doi:10.1186/s13075-020-02160-9 pmid:32252809

    CrossRefPubMed
38. 38.↵
    1. Al-Obaidi M,
    2. Saunders D,
    3. Brown S, et al

    . Evaluation of magnetic resonance imaging abnormalities in juvenile onset neuropsychiatric systemic lupus erythematosus. Clin Rheumatol 2016;35:2449–56 doi:10.1007/s10067-016-3376-9 pmid:27527090

    CrossRefPubMed
39. 39.↵
    1. Lalani TA,
    2. Kanne JP,
    3. Hatfield GA, et al

    . Imaging findings in systemic lupus erythematosus. Radiographics 2004;24:1069–86 doi:10.1148/rg.244985082 pmid:15256629

    CrossRefPubMedWeb of Science
40. 40.↵
    1. Panagopoulos D,
    2. Themistocleous M

    . Central nervous system manifestation of lupus erythematosus resembling brain abscess. Int J Pediatr Adolesc Med 2019;6:29–37 doi:10.1016/j.ijpam.2018.11.001 pmid:31304226

    CrossRefPubMed
41. 41.↵
    1. Klein C,
    2. Kleinschmidt-DeMasters BK,
    3. Liang X, et al

    . A review of neuropathological features of familial and adult hemophagocytic lymphohistiocytosis. J Neuropathol Exp Neurol 2019;78:197–208 doi:10.1093/jnen/nlz001 pmid:30726926

    CrossRefPubMed
42. 42.↵
    1. Koob M,
    2. Laugel V,
    3. Durand M, et al

    . Neuroimaging in Cockayne syndrome. AJNR Am J Neuroradiol 2010;31:1623–30 doi:10.3174/ajnr.A2135 pmid:20522568

    Abstract/FREE Full Text
43. 43.↵
    1. Livingston J,
    2. Doherty D,
    3. Orcesi S, et al

    . COL4A1 mutations associated with a characteristic pattern of intracranial calcification. Neuropediatrics 2011;42:227–33 doi:10.1055/s-0031-1295493 pmid:22134833

    CrossRefPubMedWeb of Science
44. 44.↵
    1. Grangeon L,
    2. Wallon D,
    3. Charbonnier C, et al

    ; French PFBC study group. Biallelic MYORG mutation carriers exhibit primary brain calcification with a distinct phenotype. Brain 2019;142:1573–86 doi:10.1093/brain/awz095 pmid:31009047

    CrossRefPubMed
45. 45.↵
    1. LeBlanc MA,
    2. Penney LS,
    3. Gaston D, et al

    . A novel rearrangement of occludin causes brain calcification and renal dysfunction. Hum Genet 2013;132:1223–34 doi:10.1007/s00439-013-1327-y pmid:23793442

    CrossRefPubMed
46. 46.↵
    1. Tonduti D,
    2. Orcesi S,
    3. Jenkinson EM, et al

    . Clinical, radiological and possible pathological overlap of cystic leukoencephalopathy without megalencephaly and Aicardi-Goutières syndrome. Eur J Paediatr Neurol 2016;20:604–10 doi:10.1016/j.ejpn.2016.03.009 pmid:27091087

    CrossRefPubMed
47. 47.↵
    1. Prinz M,
    2. Knobeloch KP

    . Type I interferons as ambiguous modulators of chronic inflammation in the central nervous system. Front Immun 2012;3:67 doi:10.3389/fimmu.2012.00067 pmid:22566948

    CrossRefPubMed
48. 48.↵
    1. Rice GI,
    2. Meyzer C,
    3. Bouazza N, et al

    . Reverse-transcriptase inhibitors in the Aicardi–Goutières syndrome. N Engl J Med 2018;379:2275–77 doi:10.1056/NEJMc1810983

    CrossRef